Silo Pharma (Nasdaq: SILO) has initiated its cryptocurrency treasury technique with its first purchases of Ethereum (ETH) and Solana (SOL) tokens. The corporate, which operates as a developmental-stage biopharmaceutical and cryptocurrency treasury firm, plans to stake these tokens for income technology and capital appreciation.
CEO Eric Weisblum expressed confidence in decentralized blockchain and DeFi platforms, highlighting the corporate’s dedication to incorporating digital property into its treasury holdings. This strategic transfer goals to help Silo’s biopharmaceutical property improvement whereas positioning the corporate for blockchain and real-world asset tokenization initiatives.
Silo Pharma (Nasdaq: SILO) ha avviato la sua strategia di tesoreria in criptovalute con i primi acquisti di Ethereum (ETH) e Solana (SOL) tokens. L’azienda, operante come biopharmaceutical in sviluppo e come società di tesoreria cripto, intende mettere in stake questi token per generare reddito e apprezzamento del capitale. Il CEO Eric Weisblum ha espresso fiducia nelle piattaforme blockchain decentralizzate e DeFi, sottolineando l’impegno a integrare asset digitali nelle riserve della società. Questa mossa strategica punta a supportare lo sviluppo degli asset biopharmaceutical dell’azienda e a posizionarla per iniziative di tokenizzazione su blockchain e di asset reali nel mondo.
Silo Pharma (Nasdaq: SILO) ha iniciado su estrategia de tesorería con criptomonedas con las primeras compras de Ethereum (ETH) y Solana (SOL). La compañía, que opera como empresa biofarmacéutica en desarrollo y gestora de tesorería cripto, planea apostar estos tokens para generar ingresos y apreciación del capital. El CEO Eric Weisblum expresó confianza en las plataformas blockchain descentralizadas y DeFi, destacando el compromiso de incorporar activos digitales a sus reservas. Este movimiento estratégico tiene como objetivo respaldar el desarrollo de los activos biofarmacéuticos de Silo y posicionarla para iniciativas de tokenización en blockchain y de activos del mundo actual.
Silo Pharma (Nasdaq: SILO)가 암호화폐 보유 전략을 시작했고 Ethereum (ETH)와 Solana (SOL) 토큰의 최초 매입으로 시작했습니다. 개발 단계의 생명공학 제약 및 암호화폐 보유를 관리하는 회사로서, 이 회사는 이 토큰들을 스테이킹해 수익 창출과 자본 상승을 기대합니다. CEO인 Eric Weisblum은 분산형 블록체인 및 DeFi 플랫폼에 대한 확신을 나타내며, 디지털 자산을 현금 보유고에 포함시키려는 의지를 강조했습니다. 이 전략적 조치는 Silo의 생물의약 자산 개발을 지원하고 블록체인 및 실물 자산 토큰화 이니셔티브를 위한 위치를 확보하는 것을 목표로 합니다.
Silo Pharma (Nasdaq: SILO) a lancé sa stratégie de trésorerie en crypto-monnaies avec les premiers achats d’Ethereum (ETH) et de Solana (SOL). L’entreprise, qui opère comme une biopharmaceutique en développement et une société de trésorerie crypto, prévoit de les mettre en staking pour générer des revenus et une appréciation du capital. Le PDG Eric Weisblum a exprimé sa confiance dans les plateformes blockchain décentralisées et DeFi, soulignant son engagement à intégrer les actifs numériques dans les réserves. Cette démarche stratégique vise à soutenir le développement des actifs biopharmaceutiques de Silo et à la positionner pour des initiatives de tokenisation sur la blockchain et d’actifs du monde réel.
Silo Pharma (Nasdaq: SILO) hat seine Kryptovermögensstrategie mit den ersten Käufen von Ethereum (ETH) und Solana (SOL) Token gestartet. Das Unternehmen, das als biopharmazeutisches Unternehmen in der Entwicklungsphase sowie als Treuhandgesellschaft für Kryptowährungen agiert, plant, diese Token zu staken, um Einnahmen zu erzielen und das Kapital zu steigern. CEO Eric Weisblum äußerte Vertrauen in dezentrale Blockchain- und DeFi-Plattformen und hob das Engagement hervor, digitale Vermögenswerte in die Treasury aufzunehmen. Dieser strategische Schritt soll die Entwicklung der biopharmazeutischen Belongings von Silo unterstützen und das Unternehmen für Initiativen zur Tokenisierung von Blockchain und realen Vermögenswerten positionieren.
Silo Pharma (ناسداك: SILO) أطلقت استراتيجيتها لاحتياطي الأعمال في العملات المشفرة مع أولى عمليات الشراء لـإيثيريوم (ETH) وسولانا (SOL) بوحدات. الشركة، التي تعمل كشركة أدوية حيوية قيد التطوير وشركة خزينة للعملات المشفرة، تخطط لطرح هذه الرموز في التداول الثابت (staking) لتوليد الإيرادات وتحقيق ارتفاع في رأس المال. وأعرب الرئيس التنفيذي إيريك وايسبلوم عن ثقته في منصات البلوك تشين اللامركزية والـDeFi، مؤكدًا الالتزام بإدراج الأصول الرقمية ضمن احتياطي الشركة. تهدف هذه الخطوة الاستراتيجية إلى دعم تطوير أصولها الدوائية الحيوية والتوصل إلى مبادرات لتوكنة البلوك تشين والأصول المادية في العالم الواقعي.
Silo Pharma（纳斯达克：SILO） 已启动其加密货币储备策略，首次购买了以太坊（ETH）和Solana（SOL）代币。该公司作为处于开发阶段的生物制药企业及加密货币储备公司，计划将这些代币质押以创造收入和实现资本增值。首席执行官 Eric Weisblum 对去中心化的区块链和DeFi平台表示信心，并强调将数字资产纳入公司的金库持有。这一战略举措旨在支持 Silo 的生物制药资产开发，并将公司定位于区块链及现实世界资产代币化计划。
Optimistic
- Diversification into cryptocurrency property via ETH and SOL investments
- Implementation of staking technique for income technology
- Strategic positioning for blockchain and RWA tokenization alternatives
- Alignment with institutional crypto adoption tendencies
Unfavourable
- Publicity to risky cryptocurrency market dangers
- Potential regulatory uncertainties in crypto area
- Division of focus between biotech and crypto operations
Strategic capital deployment advances Firm’s blockchain treasury mannequin and biopharma improvement initiatives
SARASOTA, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Firm”), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury firm, in the present day introduced its preliminary purchases of crypto tokens beneath its just lately introduced cryptocurrency treasury technique focusing on multi-chain asset progress.
The Firm’s acquisition of Ethereum (ETH) and Solana (SOL) tokens marks step one towards incorporating cryptocurrency into its treasury holdings and lays the inspiration for Silo’s broader blockchain and actual world asset (RWA) tokenization initiatives. The funding underscores the Firm’s perception within the long-term worth of digital property and the potential of underlying blockchain expertise to form the way forward for biotechnology.
“Our preliminary purchases of Ethereum and Solana mirror our deep conviction in decentralized blockchain and decentralized finance because the main good contract platforms,” stated Eric Weisblum, CEO of Silo. “We have now begun staking the tokens for income technology and capital appreciation to additional strengthen our monetary place and help the scientific development of our biopharmaceutical property.”
Silo’s complete digital property technique aligns with the accelerating adoption of digital property by institutional buyers and world enterprises, supported by a regulatory panorama that’s steadily evolving to allow broader market acceptance
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury firm. Its therapeutic focus is on addressing underserved circumstances, together with stress-induced psychiatric issues, persistent ache, and central nervous system (CNS) ailments. The Firm’s portfolio contains modern applications equivalent to SPC-15 for PTSD, SP-26 for fibromyalgia and persistent ache, and preclinical property focusing on Alzheimer’s illness and a number of sclerosis. Silo’s analysis is performed in collaboration with main universities and laboratories. silopharma.com
Ahead-Wanting Statements
This information launch accommodates “forward-looking statements” inside the which means of the “secure harbor” provisions of the Personal Securities Litigation Reform Act of 1995. These statements are recognized utilizing phrases “may”, “consider”, “anticipate”, “intend”, “estimate”, “count on”, “might”, “proceed”, “predict”, “potential”, and related expressions which might be meant to establish forward-looking statements. Such statements contain recognized and unknown dangers, uncertainties, and different elements that might trigger the precise outcomes of Silo Pharma, Inc. (“Silo” or “the Firm”) to vary materially from the outcomes expressed or implied by such statements, together with modifications to anticipated sources of revenues, future financial and aggressive circumstances, difficulties in creating the Firm’s expertise platforms, retaining and increasing the Firm’s buyer base, fluctuations in shopper spending on the Firm’s merchandise and different elements. Accordingly, though the Firm believes that the expectations mirrored in such forward-looking statements are affordable, there could be no assurance that such expectations will show to be right. The Firm disclaims any obligations to publicly replace or launch any revisions to the forward-looking data contained on this press launch, whether or not on account of new data, future occasions, or in any other case, after the date of this press launch or to mirror the incidence of unanticipated occasions besides as required by regulation.
Contact
800-705-0120
investors@silopharma.com
FAQ
What cryptocurrencies did Silo Pharma (SILO) put money into for its treasury technique?
Silo Pharma made preliminary investments in Ethereum (ETH) and Solana (SOL) tokens as a part of its cryptocurrency treasury technique.
How does Silo Pharma plan to generate income from its crypto investments?
Silo Pharma plans to stake its Ethereum and Solana tokens for income technology and capital appreciation to help its monetary place.
What’s the goal of Silo Pharma’s cryptocurrency treasury technique?
The technique goals to incorporate digital property into treasury holdings, generate income via staking, and help the corporate’s biopharmaceutical property whereas positioning for blockchain and RWA tokenization initiatives.
Who’s main Silo Pharma’s cryptocurrency funding initiative?
Eric Weisblum, CEO of Silo Pharma, is main the cryptocurrency funding initiative, expressing conviction in decentralized blockchain and DeFi platforms.
How does this crypto funding align with Silo Pharma’s enterprise mannequin?
The funding aligns with Silo’s evolution as a diversified developmental-stage biopharmaceutical and cryptocurrency treasury firm, positioning it for each biotech improvement and blockchain alternatives.
